Tuesday, Aadi Bioscience Inc. (NASDAQ:AADI) announced it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating ...

Aadi’s initial focus is on treating patients with aberrant TSC1 or TSC2 genes, tumor suppressors that when mutated are the ...

(c) ESC-RCC is positive for CK20 expression. (d) This ESC-RCC harbors a TSC2 (c.292del p.R98Gfs*8) mutation. Advances in immunohistochemical and molecular technologies have led to the identification ...

The opposite effect was observed in cells that were deficient for the tuberous sclerosis complex (TSC; an endogenous negative regulator of mTOR activity), in which mTOR is hyperactive: Tsc2 − ...

Tuberous sclerosis complex is associated with radiologically visible abnormalities of brain structure, principally tubers and subependymal nodules. We reviewed the literature on neuroimaging of ...

It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in ...

受全球经济下行压力和生物制药资本寒冬影响，生物医药行业裁员现象日益普遍。裁员原因包括被并购、产品开发失利、业务重组、降低管理成本等多方面。2024年8月，又有一些公司正在勒紧裤腰带裁员，详情下表所示。

而富马酸会通过与ATP竞争性结合死亡关联蛋白激酶1（DAPK1），抑制DAPK1及其下游的TSC2-mTORC1通路活性，使CD8 + T细胞的活化和抗肿瘤功能受损，因此ME2 ...

Peritoneal Tumor DNA as a Prognostic Biomarker in Gastric Cancer: A Systematic Review and Meta-Analysis In addition to the some of the above studies being retrospective, the conflicting data between ...

8月23日，据马萨诸塞州政府官网，基因编辑公司Tome Biosciences将于11月裁员131人。该公司员工数正好超过130人，但发言人未对裁员一事发表评论。 Tome ...

the trial fell short of delivering what we believe would be required to support an accelerated approval in the broad TSC1/TSC2 inactivating mutations indication. We look forward to providing the ...